PerkinElmer, Inc. Expands Screening Services to Detect Lysosomal Storage Disorders in Newborns

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, announced today that its newborn screening laboratory service, PerkinElmer Genetics, has launched a new panel to screen for six Lysosomal Storage Disorders (LSDs) as an addition to its current newborn testing and diagnostics portfolio. The LSD Screening Panel tests for Krabbe disease, Gaucher’s disease, Niemann-Pick disease (Type A and Type B), Pompe disease, Fabry disease and MPS I.

MORE ON THIS TOPIC